<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) November 7, 2000
------------------------------
ONYX PHARMACEUTICALS, INC.
--------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-28298 94-3154463
--------------------------------------------------------------------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
3031 Research Drive, Richmond, California 94806
--------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (510) 222-9700
----------------------
NOT APPLICABLE
--------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE>
ITEM 9. Regulation FD Disclosure
Pursuant to Regulation FD, information is being furnished below with
respect to presentations made by scientists and clinical investigators of
Onyx Pharmaceuticals, Inc. ("Onyx"), on November 7, 2000. Attached and
incorporated herein by reference are abstracts of these presentations given
at the EORTC/NCI/AACR, November 7, 2000 Conference. These abstracts are being
furnished under Item 9, as Exhibits 99.1, 99.2, 99.3, and 99.4, attached
hereto.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
ONYX PHARMACEUTICALS, INC.
Date: January 16, 2001 By: /s/ Gregory Giotta
-----------------------------------
Name: Gregory Giotta, Ph.D., J.D.
Title: Vice President and Chief Legal Counsel
<PAGE>
EXHIBIT INDEX
Exhibit
Number Description of Document
--------------------------------------------------------------------------------
99.1 Abstract, Introduction and Summary
Johnson et al., "Adenovirus targeting deregulation of the RB tumor
suppressor pathway in cancer cells demonstrate potent anti-tumor
activity."
99.2 Abstract, Introduction, Strategy and Conclusion
Laquerre et al., "p53-selectively replicating adenoviruses expressing
the cytosine deaminase prodrug converting enzyme."
99.3 Abstract and Study Summary
Reid et al., "Intra-arterial administration of a replication-selective
adenovirus CI-1042 (ONYX-015) in patients with colorectal carcinoma
metastatic to the liver: safety, feasibility and biological activity."
99.4 Abstract, Summary and Conclusion
Shen et al., "Analyses of single amino acid substitution mutants of
adenovirus type 5 E1B-55K protein."
